Ad blocking detected

Thank you for visiting We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Club
$299/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Oncolytics Biotech Inc. (T:ONC)

Business Focus: Biotechnology & Medical Research

This company is also listed in the United States as ONCY on the NASDAQ. Click here to get the live US quote and see if there are any SEC insider filings..
Sector:  Healthcare Industry:  Biotechnology & Medical Research
See Regulatory Filings on SEDAR
Company Contact
Address: 1167 Kensington Cres Nw Suite 210
Calgary Alberta Canada T2n 1X7
Tel: 1-403-6707377
IR: See website
Key People
Wayne F. Pisano
Independent Chairman of the Board
Matthew C. Coffey
President, Chief Executive Officer, Director
Kirk J. Look
Chief Financial Officer
Andrew De Guttadauro
Global Head of Business Development, President, Oncolytics Biotech (U.S.) Inc.
Allison Hagerman
Vice President - Product Development
Rita Laeufle
Chief Medical Officer
Michael Moore
Vice President, Investor Relations & Corporate Communications
Business Overview
Oncolytics Biotech Inc. is a development-stage company. The Company is focused on the development of REOLYSIN, its cancer therapeutic. The Company's clinical program is made up of a registration program that includes muscle-invasive bladder cancer and glioma cancer, over six randomized Phase II clinical trials and approximately six other investigative clinical trials. The Company focuses on the registration of REOLYSIN in approximately two indications, including the neoadjuvant treatment of muscle-invasive bladder cancer and the treatment of glioblastoma. The Company has conducted a single arm United States Phase II non-small cell lung cancer (NSCLC) trial and a single arm United States Phase II pancreatic cancer trial for REOLYSIN. The Company is also engaged in conducting a Phase Ib trial for REOLYSIN and chemotherapy in combination with pembrolizumab in its Checkpoint Inhibitor Program.
Financial Overview
For the nine months ended 30 September 2020,Oncolytics Biotech Inc. revenues was not reported. Net lossdecreased 4% to C$13.2M. Lower net loss reflects Change infair value ofwarrant derivativ increase from C$122K(expense) to C$3.7M (income), Foreign exchange (loss) gainincrease from C$145K (expense) to C$393K (income), Non-cashshare based compensation decrease of 31% to C$226K(expense).
Employees: 23 as of Dec 31, 2019
Reporting Currency: Canadian Dollars
Enterprise value: $141.80M as of Sep 30, 2020
Annual revenue (TTM): $0.00M as of Sep 30, 2020
EBITDA (TTM): -$23.76M as of Sep 30, 2020
Net annual income (TTM): -$32.58M as of Sep 30, 2020
Free cash flow (TTM): -$23.62M as of Sep 30, 2020
Net Debt Last Fiscal Year: N/A
Shares outstanding: 43,298,907 as of Oct 30, 2020
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization